Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Current Neurology and Neuroscience Reports|June 10, 2022
Multiple Sclerosis Management During the COVID-19 PandemicChris Hollen, Jacqueline BernardCurrent Neurology and Neuroscience Reports|March 1, 2021
Telehealth in Multiple Sclerosis Clinical Care and ResearchXinran Maria Xiang, Jacqueline BernardTranslational Neurodegeneration|December 6, 2012
Post subthalamic area deep brain stimulation for tremors: a mini-reviewTao Xie, Jacqueline Bernard, Peter WarnkePlos One|May 26, 2017
Correction: Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot studyGarrick D Talmage, Oscar J M Coppes, Adil Javed, et al.Plos One|April 21, 2017
Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot studyGarrick D Talmage, Oscar J M Coppes, Adil Javed, et al.Journal of the Neurological Sciences|December 19, 2017
High resolution retinal scanning reveals regional structural differences between MS and NMOSD optic neuritis regardless of antibody statusMarcel Bertsch-Gout, Richard Loeb, Ashley K Finch, et al.Journal of Neurology|August 22, 2016
Evaluation of parkinsonism and striatal dopamine transporter loss in patients with spinocerebellar ataxia type 6Tao Xie, Daniel Appelbaum, Jacqueline Bernard, et al.Multiple Sclerosis and Related Disorders|April 17, 2015
Severe early bilateral macular edema following fingolimod therapyOscar Jim Michael Coppes, Ismael Gutierrez, Anthony T Reder, et al.Neuro-Ophthalmology (Aeolus Press)|December 9, 2016
Bilateral Optic Disc Swelling Following Anastrozole TherapyOscar Jim Michael Coppes, Rimas V Lukas, Gini F Fleming, et al.Plos One|December 22, 2018
Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatmentFredrika Koskimäki, Jacqueline Bernard, Jeong Yong, et al.Pageof 2